Pictured: A/Prof Peter van Wijngaarden (left) and Dr Xavier Hadoux (right) of Enlighten Imaging Pty Ltd are developing a novel hyperspectral retinal imaging platform for next generation AI diagnostics with support from the BioMedTech Horizons program. Image credit: Anna Carlile.
Project title: A novel hyperspectral retinal imaging platform for next generation AI diagnostics
The use of Artificial Intelligence in ophthalmology has centred on the analysis of retinal photographs in the primary care setting.
Though promising, these systems are constrained by the limitations of conventional photography. Enlighten Imaging have developed a novel imaging platform using hyperspectral imaging in combination with machine learning to extract a range of biomarkers of eye and central nervous system diseases that are not detectable using standard approaches. The project acquires images of the retina with many different colours (wavelengths) of light, providing a wealth of information about the retinal structure, over and above that acquired with conventional imaging.
This technology is set to disrupt the provision of primary eye care, improving outcomes for people around the world. Enlighten Imaging is an Australian company incubated at the Centre for Eye Research Australia that is taking this technology to the global stage for glaucoma, diabetic retinopathy, age related macular degeneration and Alzheimer’s disease. The imaging platform is readily integrated into existing clinical workflows, providing a step-change improvement on standard photography.
The company's competitive advantages are a strong base of preliminary data; well advanced camera prototypes and a suite of algorithms with proven performance in biomarker detection. They have a strong intellectual property position and an active research and development team.
BMTH Round: Two
- MTPConnect Grant: $1,000,000
- Industry Contribution: $1,650,000
Duration: April 2020 - September 2022 (Ongoing)
Contact: Dr Xavier Hadoux